PECA Labs, Inc.

PECA Labs, Inc. is a medical technology company specializing in innovative cardiovascular implants, focusing on advanced vascular grafts and heart valves designed for both pediatric and adult patients. PECA Labs, Inc. is dedicated to developing advanced cardiovascular implants, particularly next-generation vascular grafts and heart valves.

The company was co-founded by Arush Kalra, Doug Bernstein, Enes Karahançer, and Jamie Quinterno. Its headquarters is located in Pittsburgh, US. The company successfully raised USD 13. 93 mn in Series A funding on December 12, 2024, bringing their total amount raised to USD 13.

93 mn and their current company valuation to USD 42. 10 mn. PECA Labs specializes in advanced cardiovascular implants, particularly focusing on next-generation vascular grafts and heart valves designed for both pediatric and adult patients. The company’s flagship products include radiopaque vascular grafts that feature integrated radiopaque indicators for advanced noninvasive visualization, and the MASA Valve, designed for pulmonary valve reconstruction with fully-polymeric leaflets that enhance durability and performance.

These products address challenges in treating congenital heart defects and other cardiovascular conditions, primarily serving hospitals and surgical centers in the United States, with clinical trials ongoing and plans for international market expansion. PECA Labs generates revenue through direct sales and partnerships with healthcare institutions that utilize its innovative vascular grafts and valves. The primary transaction structure involves B2B sales to hospitals and surgical centers, where specialized cardiovascular surgeons implement the products during surgical procedures. Revenue is primarily driven by the commercialization of the proprietary MASA Valve and radiopaque grafts, with pricing strategies reflecting the premium features of these advanced medical devices.

With ongoing clinical trials and regulatory approvals, the company anticipates increased demand for its products, enhancing its revenue potential within the cardiovascular healthcare market. PECA Labs plans to leverage its recent Series A funding of USD 13. 93 mn, raised in December 2024, to support the development of new products including enhancements to its MASA Valve and additional vascular graft options. The company aims to expand its market presence, targeting international regions for growth by late 2025.

The funding will be utilized to accelerate product development and support entry into new geographic markets while continuing to improve the efficacy of its existing offerings.